biotech
60 stories related to this topic, newest first.
focustaiwan.twExperimental Lung Cancer Drug Cuts Death Risk by 34% in China Trial
An ivonescimab-based therapy from Akeso and Summit Therapeutics lowered death risk by 34% versus standard care in a late-stage Chinese study. Median survival reached 27.9 months compared with 23.7 months for patients on a PD-1 drug plus chemotherapy.
StatIvonescimab Shows 34% Reduction in Death Risk vs. Standard Therapy in China-Only Squamous NSCLC Trial
Data from a China-only trial of ivonescimab were presented May 31, 2026, at the American Society of Clinical Oncology meeting in Chicago and published simultaneously in The Lancet.
/cdn.vox-cdn.com/uploads/chorus_asset/file/24856972/236744_Withings_Body_Smart_VSong_0003.jpg)
theverge.comRetatrutide Shows 28 Percent Body Weight Reduction in Trials
Retatrutide, a triple-receptor drug targeting GLP-1, GIP, and glucagon, produced the largest average weight loss reported so far. The medication also carries additional safety considerations.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
sixthtone.comPancreatic cancer treatment advance prompts pharmaceutical deal activity
A recent medical advance in pancreatic cancer treatment has led to increased dealmaking among pharmaceutical companies. The development follows years of limited progress in the disease area.
The Sydney Morning HeraldAustralian Writer Describes Antidepressant Withdrawal While Discussing U.S. Health Secretary's Proposal
A freelance writer detailed personal withdrawal symptoms after stopping venlafaxine. The account references U.S. Health Secretary Robert F. Kennedy Jr.'s announced campaign to reduce psychiatric drug use.
insidermonkey.comSpyre Therapeutics Director Jeffrey Albers Resigns from Board
Spyre Therapeutics disclosed the resignation of director Jeffrey Albers effective May 27, 2026. The move triggers standard SEC reporting obligations and leaves the board with one fewer independent director until a replacement is named.
benzinga.comEnveric Biosciences Reports Director and Officer Changes in 8-K Filing
Enveric Biosciences disclosed the departure of a director and the election of a new principal officer in an SEC Form 8-K filed on May 29, 2026. The changes trigger updated disclosures on board composition and executive leadership that investors and regulators will review in the c…
MarketWatchCVS to Cover Lilly GLP-1 Medications for Weight Management
CVS will add coverage for two GLP-1 medications produced by Eli Lilly. The decision expands access for millions of Americans seeking treatment for weight management.
manilatimes.netKnight Therapeutics to Present at Jefferies 2026 Healthcare Conference
Knight Therapeutics Inc. announced that its president and chief executive officer will present at the Jefferies 2026 Healthcare Conference on June 4, 2026. The presentation is scheduled for 2:35 PM ET in New York City.
The IndependentGSK Hepatitis B Drug Shows Functional Cure in 20 Percent of Trial Patients
Two international studies found that bepirovirsen produced sustained viral suppression in roughly one-fifth of participants after treatment ended. The drug is under FDA fast-track review with a decision expected in October.
StatGSK Drug Achieves Functional Cure in 19-20% of Hepatitis B Patients
Two Phase 3 trials showed GSK's bepirovirsen produced functional cures in nearly one-fifth of chronic hepatitis B patients. Current nucleoside analogue treatments reach functional cures in only 1-3% of cases. The company has submitted the drug for regulatory approval.
EuronewsFrance to Reimburse Weight-Loss Drugs Starting Mid-June
France will cover 65 percent of the cost of Wegovy and Mounjaro for obesity patients from 15 June, becoming the first European country to add the drugs to standard national health coverage.
finance.yahoo.comChina pharma industry unaffected by Beijing tech deal reviews, JW chief says
The head of JW stated that Beijing's review of sensitive technology transactions has not affected China's pharmaceutical sector. The comment addresses ongoing government scrutiny of certain deals.
video.foxbusiness.comUBS Says GLP-1 Weight-Loss Drugs Reduce Restaurant Sales
UBS stated that rising use of GLP-1 weight-loss drugs could lower restaurant sales as users reduce calorie intake and eat out less. The bank expects restaurants to adjust menus with smaller portions and healthier items.
StatEli Lilly to Acquire Three Vaccine Developers for Up to $4 Billion
Eli Lilly announced Tuesday it will purchase Curevo, LimmaTech Biologics, and Vaccine Company. The combined deals could reach nearly $4 billion and target pathogens linked to long-term health issues.
ForbesAstraZeneca Launches Clean Heat Program for Supplier Network
AstraZeneca is rolling out a program to cut heat-related emissions across its pharmaceutical supply chain. The initiative works with Secaro and ERM to map energy use and finance efficiency upgrades at supplier sites.
StatEli Lilly to Acquire Three Early-Stage Vaccine Developers
Eli Lilly announced Tuesday it will purchase three vaccine companies for a combined total that could reach nearly $4 billion. The acquisitions expand the company's presence in infectious-disease research.
prnewswire.comResearchers Report Kilogram-Scale Synthesis of Cholesterol Drug Enlicitide
A Science study describes a new production method for enlicitide, a peptide in Phase 3 trials for lowering LDL cholesterol. The route uses engineered enzymes and crystallization steps to reduce reaction count and raise yield.
rte.ieDenmark Raises 2026 GDP Growth Forecast on Pharmaceutical Sales
The Danish economy ministry increased its growth outlook for this year. Stronger-than-expected pharmaceutical exports, led by Novo Nordisk, prompted the revision.
The GuardianUK startup launches drug crystallisation unit to International Space Station
BioOrbit sent a compact unit aboard a SpaceX rocket on 15 May to grow protein crystals in microgravity. The crystals are intended for use in self-injected cancer treatments after return to Earth.
forbes.comForus Reaches $1 Billion Valuation With AI Prescription Software
Forus announced it reached a $1 billion valuation after raising $160 million in total funding. The company reported annualized revenue above $50 million so far this year.
ForbesSpaceX Files IPO Papers Ahead of Next Starship Test Flight
SpaceX submitted IPO registration documents on Wednesday. The filing highlights Starship as central to future revenue plans while noting ongoing development delays.
ecns.cnPodcast Discusses Biotech Summit and China Competition
The weekly biotech podcast covered conversations from a recent health care and science summit. Topics included research publication practices and the role of AI in drug development.
ncbi.nlm.nih.govGLP-1 Drug Effects on Cancer Remain Unresolved
Medical researcher Eric Topol stated that any potential link between GLP-1 drugs and cancer incidence is not yet confirmed. He noted that observed effects may relate to weight loss rather than independent mechanisms.
finance.yahoo.comEli Lilly Reports Retatrutide Helped Patients Lose 70 Pounds in Trial
Eli Lilly announced clinical trial results showing its experimental obesity drug retatrutide produced greater weight loss than its existing treatments Zepbound and Wegovy. The company said participants lost an average of 70 pounds over 80 weeks.
ncbi.nlm.nih.govStudies Examine Weight-Loss Drugs and Cancer Outcomes
Recent research has examined whether medications such as Ozempic and Zepbound affect tumor progression and patient survival. The findings remain preliminary and require further study.
StatMerck-Kelun Drug Reduced Lung Cancer Progression Risk by 65 Percent in Trial
Phase 3 study results showed that a targeted chemotherapy developed by Kelun-Biotech and licensed to Merck reduced tumor progression risk by 65 percent in patients with advanced non-small cell lung cancer. A preliminary survival benefit was observed but requires longer follow-up…
SemaforNovo Nordisk Loses Canadian Patent on Ozempic
Generic versions of Ozempic became available in Canada this week after Novo Nordisk did not renew its patent. The company said its intellectual property decisions are made at the global level.
app.buzzsumo.comFragrance Tech Startup Patina Raises $2 Million
Patina announced a $2 million funding round led by investors including Betaworks and True Ventures. The company develops scent molecules using molecular design and machine learning.
Nbc NewsEli Lilly Weight Loss Drug Retatrutide Shows Up to 30 Percent Body Weight Loss in Trial
Eli Lilly reported that its experimental drug retatrutide produced average weight loss of 28 percent after 80 weeks and up to 85 pounds in some patients. The results come from a phase 3 trial of roughly 2,300 people and remain comparable to outcomes from bariatric surgery.
benzinga.comEli Lilly Reports Retatrutide Weight Loss Results in Phase 3 Trial
Eli Lilly reported results from a late-stage trial of its obesity drug retatrutide. Patients who stayed on the highest dose lost an average of 28.3 percent of their body weight after 80 weeks.
CnbcEli Lilly Files Lawsuit Alleging $200 Million Trulicity Rebate Fraud
Eli Lilly filed a civil lawsuit claiming a Florida mail-order pharmacy and affiliated organizations submitted false rebate claims for its diabetes drug Trulicity. The complaint names several individuals connected to the Church of God in Christ.
prnewswire.comVirginia Governor Vetoes Bill Creating Drug Cost Advisory Panel
Virginia Gov. Abigail Spanberger vetoed legislation that would have created an advisory panel to lower prescription drug costs. The panel would have used Medicare benchmarks and set upper payment limits.
medpagetoday.comIpsen Reports Head-to-Head Trial Results Comparing Dysport and Botox for Upper Limb Spasticity
Ipsen announced results from a Phase IV trial that compared Dysport and Botox in adults with upper limb spasticity. The study met its primary safety endpoint and a secondary efficacy endpoint showing longer duration of response for Dysport.
ecns.cnSTAT Breakthrough West 2026 Agenda Released
The 2026 agenda for Breakthrough West is now live. Organizers invite attendees to explore speakers and themes shaping the event.
marketwatch.comDrugmaker Shares Fall After Skin Cancer Drug Trial Misses Target
Shares of an unnamed drugmaker fell in premarket trading after the company reported that a late-stage clinical trial of a skin cancer medication did not meet its primary goal. The announcement came before regular market hours.
The Japan TimesJapan Sends Antiviral Drug Avigan to Britain After Hantavirus Outbreak
The Japanese government supplied antiviral drug Avigan to Britain on Friday after a hantavirus outbreak on a cruise ship. Britain accepted passengers including a Japanese national and requested the drug under a bilateral agreement.
StatU.K. Advocacy Groups Threaten Legal Action Over U.S. Pharma Trade Deal
Two advocacy groups are demanding the United Kingdom revoke regulations tied to a recent pharmaceutical trade agreement with the U.S. The groups say the regulations could allow outside influence on decisions about medicine cost-effectiveness and have stated they are preparing cou…
ncbi.nlm.nih.govApnimed Prepares FDA Filing for Sleep Apnea Pill
Apnimed plans to seek FDA approval for a nightly pill developed from two existing drugs. The treatment aims to address obstructive sleep apnea, which affects up to 80 million people in the U.S.
japantimes.co.jpDistributor Recommends Stopping Use of Amgen Drug Tavneos in Japan
The company that sells Amgen’s drug Tavneos in Japan is recommending that doctors stop prescribing the medicine. The action adds to existing regulatory scrutiny of the treatment in multiple countries. Tavneos is approved for use in several markets including the United States.
themarketherald.com.auBloomwell Expands Telehealth Cannabis Prescriptions in Germany
Bloomwell, a German telehealth company founded in 2020, connects patients with doctors for medical cannabis prescriptions that can be delivered to their homes. The company has grown to serve more than 100,000 patients through a network of 60 doctors. Germany’s legal cannabis mark…
kr-asia.comBristol Myers Squibb Partners With China's Hengrui Pharma on Early-Stage Drug Development and Discovery
Bristol Myers Squibb will send four of its experimental drugs to China for early-stage clinical trials under the deal announced Tuesday. The companies will also collaborate to discover new medicines, with each contributing assets to the potentially multi-billion dollar partnershi…
StatU.S. Officials Urge Germany to Increase Payments for Medicines
Trump administration officials told the German ambassador to the United States that Germany should pay more for medicines. The message was delivered at a recent meeting, according to a person familiar with the encounter. STAT reported the development on May 15, 2026.
StatU.S. Officials Press Germany to Raise Drug Prices in Bid to Lower American Costs
U.S. officials told the German ambassador that Germany should pay more for pharmaceuticals as part of a broader effort to reduce prices paid in the United States. The meeting involved the U.S. Trade Representative and a senior health department adviser. Separately, some U.S. biot…
StatU.S. and Germany Discuss Fairer Global Split of Pharmaceutical Costs in Washington Meeting
U.S. Trade Representative Jamieson Greer and chief health department adviser Chris Klomp told German Ambassador Jens Hanefeld over breakfast that Germany should pay more for prescription drugs. The discussion included possible tariffs under Section 301 as part of a broader Trump…
ksl.comStartup Reaches $1 Billion Valuation Processing Prescription Drug Paperwork With AI
The company developed software that automates administrative tasks for prescriptions including insurance routing, prior authorizations and pharmacy selection. It reported reaching a $1 billion valuation with $160 million in total funding and annualized revenue now above $50 milli…
forbes.comNRx Pharmaceuticals to Report First-Quarter Earnings on May 18
Analysts expect NRx Pharmaceuticals to post a loss of 11 cents per share on $19.43 million in revenue. The company recently received FDA clearance to begin a clinical trial of NRX-101. Several analysts maintained Buy ratings with price targets ranging from $25 to $49.
forbes.comBankruptcy Court Approves CVS Health Sale of Omnicare to GenieRx for $250 Million
A bankruptcy court approved the sale of CVS Health’s Omnicare long-term care pharmacy network to GenieRx in a $250 million deal. The transaction is the latest step in CVS Health’s effort to focus on its more profitable operations. The sale is expected to close later in 2026.
StatRegenxbio Gene Therapy for Duchenne Muscular Dystrophy Succeeds in Trial
Regenxbio announced on May 14, 2026 that its experimental treatment produced high levels of a miniaturized muscle protein, clearing the path for an FDA submission. The Rockville, Md.-based company aims to offer a safer and more effective option than Sarepta Therapeutics’ Elevidys…
marketwatch.comApellis Pharmaceuticals Completes Change in Control and Faces Nasdaq Delisting
Apellis Pharmaceuticals reported a change in control, entry into a material definitive agreement, termination of a prior agreement, and completion of an asset disposition in an 8-K filed May 14 2026. The filing triggers immediate Nasdaq delisting proceedings and requires the comp…
thestreet.comCompass Pathways Reports Positive Phase 3 Data for COMP360 in Treatment-Resistant Depression
Compass Pathways announced positive results from two Phase 3 trials of COMP360 for treatment-resistant depression during its first-quarter 2026 earnings call. The company has begun a rolling NDA submission with the FDA and received a Commissioner's National Priority Voucher. Offi…
japantimes.co.jpShionogi Antiviral Pill Cuts COVID-19 Infection Risk in Exposed Household Contacts
An experimental pill developed by Shionogi reduced the risk of COVID-19 infection among people exposed to the virus at home. The study marks the first time an antiviral pill has demonstrated preventive efficacy against SARS-CoV-2 in exposed individuals. Results were published in…
interestingengineering.comGene Editing Turns Stem Cells Into Antibody-Producing Factories in Mice
A study published in the journal Science showed that editing a small number of blood-forming stem cells allowed mice to produce chosen antibodies for extended periods. The edited cells responded to vaccine boosters by increasing antibody output. The approach was tested against HI…
cnbc.comLeerink Upgrades Johnson & Johnson to Buy, Raises Sales Forecasts for Newly Launched Drugs
Leerink analysts upgraded Johnson & Johnson shares to a buy equivalent from hold on Wednesday, pointing to momentum from recently launched medicines. The firm raised its price target to $265 per share and lifted sales growth forecasts. Johnson & Johnson shares rose more than 2 pe…
citizen.co.zaSouth Africa to Begin Lenacapavir HIV Prevention Injections in Mpumalanga on June 5
Health Minister Dr Aaron Motsoaledi announced the rollout of the twice-yearly HIV prevention drug, with stocks arriving in two weeks and initial distribution to 360 facilities in high-burden districts. The Global Fund for HIV, TB and Malaria will finance the programme for South A…
The Japan TimesJapan Adds iPS Cell-Derived Parkinson’s Treatment to National Health Insurance at ¥50 Million per Patient
An advisory panel to the health minister approved Sumitomo Pharma’s Amchepry on May 13, 2026, making it the world's first commercialized medical product derived from iPS cells. The treatment, costing ¥55.3 million ($350,600) per patient, will gain insurance coverage on May 20 wit…
livemint.comX4 Pharmaceuticals Reports Director Departure and Shareholder Votes
X4 Pharmaceuticals disclosed the departure of a board member and the results of its annual shareholder meeting in an 8-K filing. The changes trigger standard SEC follow-on disclosures and affect board composition for the clinical-stage biotech.
benzinga.comVertex Pharmaceuticals Reports Director Election and Officer Departure
Vertex Pharmaceuticals disclosed the election of a new board director and the departure of a principal officer in an 8-K filing. The changes trigger standard SEC disclosure obligations and board composition updates that affect corporate governance processes.
benzinga.comZenas BioPharma Reports First-Quarter Results and Board Changes
Zenas BioPharma Inc. filed an 8-K disclosing results of operations for the quarter ended March 31 2026 along with the election of a new director and the departure of an officer. The changes trigger updated disclosures to shareholders and potential follow-on SEC filings on executi…